HIMR, page-2

Yep, the patent on this is a slam dunk I reckon.

The bigger question is why Veyonda has not been included in any of the large COVID trials yet. With such promising phase I data, it is strange that the company has not pushed harder for this. The whole COVID trial landscape is painfully political, but I'm beginning to think that there might be something else, given NOX are not interested in funding a NOXCOVID-2 themselves. Perhaps the immune suppressing aspects of the STING inhibition is TOO high? Perhaps they are just too busy and want to prioritise elsewhere? But clearly they are still pursuing the patent and have even paid for TrackOne prioritisation so we can't rule out surprise news at any time.